Mild Hyperhomocysteinemia is an Independent Risk Factor of Arterial Vascular Disease

ABSTRACT

Evidence of a positive association between mild hyperhomocysteinemia and arterial vascular disease has been accumulating in the last decade. Mild hyperhomocysteinemia acts as an independent vascular risk factor with equal strength as hypercholesterolemia and smoking. If jointly present with hypertension and smoking, its effect seems synergistic. This could make the outcome of homocysteine-lowering intervention beneficial, particularly in cases with concomitance of conventional vascular risk factors. So far, however, data on the clinical outcome of homocysteine-lowering treatment with a simple, safe, and cheap vitamin regimen are lacking. Trials investigating a beneficial clinical effect of homocysteine-lowering treatment using folic acid in a dose ranging from 0.2 to 5 mg daily, alone or in combination with vitamin B₁₂ with or without vitamin B₆ versus placebo, are ongoing. Furthermore, exploration of the unifying mechanism by which increased homocysteine levels may lead to both arterial and venous occlusions is warranted. These lines of investigations have to provide the ultimate proof of causality of hyperhomocysteinemia in vascular disease in the near future.

KEYWORD

Hyperhomocysteinemia - vascular risk factors - B vitamins - vascular diseases

REFERENCES

• 1 Boers G HJ. Homocystinuria, a Risk Factor of Premature Vascular Disease. Clinical Research Series No 3. Dordrecht, Holland: Foris Publications 1986
• 2 Mudd S H, Skovby F, Levy H L. The natural history of homocystinuria due to cystathionine-β-synthase deficiency.  Am J Hum Genet . 1985;  37 1-31
• 3 Mudd S H, Levy H L, Skovby F I. Disorders of transsulfuration. in: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease New York: McGraw-Hill, 1995: 1279-1327
• 4 Kluijtmans L AJ, van de Heuvel L PWJ, Boers G HJ. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease.  Am J Hum Genet . 1996;  58 35-41
• 5 Sardharwalla I B, Fowler B, Robinson A J, Komrower G M. Detection of heterozygotes for homocystinuria.  Arch Dis Child . 1974;  49 553-559
• 6 Wilcken D EL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism.  J Clin Invest . 1976;  57 211-215
• 7 Boers G HJ, Schoonderwaldt H C, Schulte P BM. Heterozygosity for homocystinuria: A risk factor of occlusive cerebrovascular disease.  Clin Genet . 1983;  24 300-301
• 8 Boers G HJ, Smals A GH, Trijbels J MF. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.  N Engl J Med . 1985;  313 709-715
• 9 Clarke R, Daly L, Robinson K. Hyperhomocysteinemia: An independent risk factor for vascular disease.  N Engl J Med . 1991;  324 1149-1155
• 10 Boushey C J, Beresford S AA, Omenn G S. A quantitive assessment of plasma homocysteine as a risk factor for vascular disease.  JAMA . 1995;  274 1049-1057
• 11 Boers G HJ. Peripheral arterial disease. in: Carmel R, Jacobsen D, eds Homocysteine in Health and Disease. New York: Cambridge University Press 2000
• 12 Graham, D aly, Refsum H M. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.  JAMA . 1997;  277 1775-1781
• 13 Refsum H, Ueland P M, Nygård O, Vollset S E. Homocysteine and cardiovascular disease.  Annu Rev Med . 1998;  49 31-62
• 14 Alfthan G, Pekkanen J, Jauhiainen M. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study.  Atherosclerosis . 1994;  106 9-19
• 15 Evans R W, Shaten B J, Hempel J D, Cutler J A, Kuller L H. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial.  Arterioscler Thromb Vasc Biol . 1997;  17 1947-1953
• 16 Verhoef P, Hennekens C H, Allen R H. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery.  Am J Cardiol . 1997;  79 799-801
• 17 Stampfer M J, Malinow M R, Willet W C. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians.  JAMA . 1992;  268 877-881
• 18 Verhoef P, Hennekens C H, Malinow M R. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.  Stroke . 1994;  25 1924-1930
• 19 Arnesen E, Refsum H, Bonaa K H. Serum total homocysteine and coronary heart disease.  Int J Epidemiol . 1995;  24 704-709
• 20 Perry I J, Refsum H, Morris R W. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.  Lancet . 1995;  346 1395-1398
• 21 Chasan-Taber L, Selhub J, Rosenberg I H. A prospective study of folate and vitamin B₆ and risk of myocardial infarction in US physicians.  J Am Coll Nutr . 1996;  15 136-143
• 22 Nygård O, Nordrehaug J E, Refsum H. Plasma homocysteine levels and mortality in patients with coronary artery disease.  N Engl J Med . 1997;  337 230-236
• 23 Folsom A R, Nieto F J, McGovern P G. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study.  Circulation . 1998;  98 204-210
• 24 Stehouwer C D, Weijenberg M P, Van den Berg M. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: A 10-year follow-up.  Arterioscler Thromb Vasc Biol . 1998;  18 1895-1901
• 25 Ubbink J B, Fehily A M, Pickering J, Elwood P C, Vermaak W J. Homocysteine and ischaemic heart disease in the Caerphilly cohort.  Atherosclerosis . 1998;  140 349-356
• 26 Wald N J, Watt H C, Law M R. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention.  Arch Intern Med . 1998;  158 862-867
• 27 Whincup P H, Refsum H, Perry I J. Serum homocysteine and coronary heart disease: Prospective study in middle-aged men.  Neth J Med . 1998;  52 S36
• 28 Bostom A G, Silbershatz H, Rosenberg I H. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women.  Arch Intern Med . 1999;  159 1077-1080
• 29 Bots M L, Launer L J, Lindemans J. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: The Rotterdam Study.  Arch Intern Med . 1999;  159 38-44
• 30 Ridker P M, Manson J E, Buring J E. Homocysteine and risk of cardiovascular disease among postmenopausal women.  JAMA . 1999;  281 1817-1821
• 31 Stehouwer C D, Gall M A, Hougaard P, Jakobs C, Parving H H. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria.  Kidney Int . 1999;  55 308-314
• 32 Taylor Jr L M, Moneta G L, Sexton G J, Schuff R A, Porter J M. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease.  J Vasc Surg . 1999;  29 8-19
• 33 Malinow M R, Ducimetiere P, Luc G. Plasma homocyst(e)ine levels and graded risk for myocardial infaction: Findings in two populations at contrasting risk for coronary artery disease.  Atherosclerosis . 1996;  126 27-34
• 34 Pancharuniti N, Lewis C A, Sauberlich H E. Plasma homocyst(e)ine, folate, and vitamin B₁₂ concentrations and risk of early-onset coronary artery disease.  Am J Clin Nutr . 1994;  59 940-948
• 35 von Eckardstein A, Malinow R, Upson B. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men.  Arterioscler Thromb . 1994;  14 460-464
• 36 Malinow M R, Nieto F J, Szklo M, Chambless L E, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults.  Circulation . 1993;  87 1107-1113
• 37 Selhub J, Jacques P, Bostom A G. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis.  N Engl J Med . 1995;  332 286-291
• 38 Taylor L M, DeFrang R D, Harris E J, Porter J M. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease.  J Vasc Surg . 1991;  13 128-136
• 39 van den Berg M, Stehouwer C DA, Bierdrager E, Rauwerda J A. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease.  Arterioscler Thromb Vasc Biol . 1996;  16 165-171
• 40 Bergmark C, Mansoor M A, Swedenborg J. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50.  Effect of smoking and extent of disease. Eur J Vasc Surg . 1993;  7 391-396
• 41 Boers G HJ, Yap S, Naughten E, Wilcken B. The treatment of high homocysteine concentration in homocystinuria. Biochemical control in patients and their vascular outcome. In: Robinson K, ed. Homocysteine and Vascular Disease. Dordrecht The Netherlands: Kluwer Academic Publishers, 2000: 387-411
• 42 van<&&>Guldener C, Stehouwer C DA. Hyperhomocysteinemia vascular pathology and endothelial dysfunction.  Semin Thromb Hemost . 2000;  26 281-289
• 43 Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: Review of the randomized trials of homocysteine-lowering vitamin supplements.  Semin Thromb Hemost . 2000;  26 341-348
• 44 Robinson K, Arheart K, Refsum H. Low circulating folate and vitamin B₆ concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease.  Circulation . 1998;  97 437-443
• 45 Rimm E B, Willet W C, Hu F B. Folate and vitamin B₆ from the diet and supplements in relation to the risk of cardiovascular disease among women.  JAMA . 1998;  279 359-364
• 46 Verhaar M C, Wever R M, Kastelein J J. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia.  Circulation . 1998;  97 237-241